

Protein Labeling - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-06-01 | 105 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

Protein Labeling Market Analysis

The protein labelling market is currently valued at USD 2.92 billion in 2025 and is forecast to reach USD 4.57 billion by 2030, translating into a steady 9.39% CAGR. Demand is propelled by breakthroughs that allow site-specific tags with minimal impact on protein conformation, an essential requirement for today's advanced proteomics, live-cell imaging and biotherapeutic workflows. Widening use of artificial-intelligence tools for structure prediction, a growing pipeline of antibody-drug conjugates and the migration of complex bioconjugation tasks to specialist CDMOs jointly broaden commercial opportunities. At the same time, capital-intensive analytical platforms and evolving regulations around radio-labelled conjugates remain practical hurdles. Competitive intensity is rising as incumbents look to differentiate via proprietary chemistries, integrated service models and strategic alliances with drug developers.

Global Protein Labeling Market Trends and Insights

Expanding R&D in proteomics and genomics

Advances in high-resolution mass spectrometry and AI-driven modelling have sharply raised the volume and depth of protein characterisation studies. The release of ESM-3 and AlphaFold 3 in 2024 improved structure-prediction accuracy, allowing researchers to pinpoint accessible residues for selective tagging and production. Funding programs across the United States and Europe now prioritise multi-omics pipelines that depend on robust labelling chemistries for quantitation and spatial mapping.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

These dynamics sustain premium pricing for next-generation probes and herald broader uptake of high-throughput workflows in academic cores and translational-medicine centres.

Growing application in drug discovery and development

Roughly 40% of investigational drugs now focus on historically undruggable proteins, elevating the role of homogeneous, site-specific labelling. Antibody-drug conjugate pipelines, currently exceeding 360 clinical studies, require precise linker-payload ratios for efficacy. Targeted protein degradation platforms similarly depend on live-cell tags that monitor real-time proteolysis. These use cases expand addressable demand across reagents, instrumentation and custom-conjugation services.

Limitations of protein labelling assays and methods

Large fluorescent tags above 25 kDa altered sub-cellular localisation in 42% of tested proteins, and nanobody conjugates showed 38% variability in binding efficiency across labs. Such inconsistencies raise validation requirements, extend project timelines and increase consumable usage, particularly in regulated environments.

Other drivers and restraints analyzed in the detailed report include:

Rising outsourcing to CDMOs/CROs / Increasing use of fluorescence-based techniques / Regulatory hurdles for protein-radioisotope conjugates /

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Reagents and kits accounted for 71.13% of protein labelling market revenues in 2024, underscoring their essential role in day-to-day workflows across discovery, diagnostics, and manufacturing. Ready-to-use chemistries simplify protocol standardisation and support reproducibility, keeping demand resilient even as new techniques emerge. Continuous improvements in dye brightness and click-ready handles sustain incremental pricing power and entice repeat purchases.

The services segment, however, is outpacing headline growth at a 10.47% CAGR. This surge reflects the escalating technical complexity of antibody-drug conjugation, targeted degradation probes and live-animal imaging agents that exceed many in-house capabilities. CDMOs are adding dedicated 1,000-2,000 L suites, such as Lonza's 2024 expansion in Visp, to accommodate large-scale payload conjugation and fill-finish tasks. The protein labelling market size for outsourced projects is projected to expand steadily as pipeline sponsors seek rapid, GMP-compliant solutions.

Immunological techniques remained the largest slice of the protein labelling market with a 34.37% share in 2024, benefiting from decades of optimisation in ELISA, western blot and immunohistochemistry. High throughput and clinically validated protocols ensure enduring relevance in biomarker verification, lot-release testing and routine pathology.

Cell-based assays, however, record the most rapid advance at 11.13% CAGR as researchers prioritise physiologically relevant readouts in oncology, neurology and regenerative medicine. Fluorescent-probe portfolios from Thermo Fisher enable real-time monitoring of receptor activation, trafficking and complex assembly. The protein labelling market share captured by dynamic live-cell platforms is set to widen as automated imaging and high-content analytics permeate screening laboratories.

The Protein Labelling Market is Segmented by Product (Reagents and Kits, Services and Other Products), Application (Immunological Techniques, Cell-Based Assays and More), Labeling Method (In-Vitro Labelling and In-Vivo Labelling), End User

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

(Pharmaceutical and Biotechnology Companies, Contract Research and Manufacturing Organisations and More) and Geography. The Market and Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America generated 37.90% of 2024 revenues, supported by robust NIH funding, a dense biopharma cluster and early adoption of next-generation labelling technologies. MIT's CuRVE breakthrough, capable of labelling tens of millions of cells in a single day, exemplifies regional leadership in disruptive methodology. A high cadence of FDA approvals for ADCs and radio-immunoconjugates further anchors commercial momentum.

Europe ranks second, buoyed by Horizon Europe grants and strong biomanufacturing corridors in Germany, the United Kingdom and France. Sartorius' acquisition of Polyplus expanded the continent's vector-production capabilities, necessitating advanced tagging for viral envelope proteins. Regulatory harmonisation is progressing, yet divergent approaches to radio-isotope handling keep market entry costs elevated.

Asia-Pacific is the fastest-growing arena, advancing at an 11.57% CAGR. Chinese CDMOs such as WuXi Biologics report vibrant demand for conjugation formats branded under WuXiBody and associated linker chemistries. National industrial policies, including China's 14th Five-Year Plan and India's BIRAC initiatives, funnel capital into proteomic infrastructure, although uneven access to high-end MS platforms persists. South Korea's rapid scale-up of antibody-drug conjugate facilities, backed by Samsung Biologics, further cements regional ascent.

List of Companies Covered in this Report:

Thermo Fisher Scientific / Merck / Danaher Corp. / Revvity / Roche / Agilent Technologies / Bio-Rad Laboratories / KMD Bioscience Co., Ltd. / Promega / LI-COR Biotech, LLC / New England Biolabs / Takara Bio / Vector Laboratories / Jena Bioscience / Lumiprobe Corp. / Biotium Inc. / Abcam / Creative Diagnostics / Cyanagen Srl / Genscript /

Additional Benefits:

The market estimate (ME) sheet in Excel format /
3 months of analyst support /

Table of Contents:

1 Introduction

1.1 Study Assumptions and Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Expanding Research and Development in Proteomics and Genomics

4.2.2 Growing Application of Protein Labeling in Drug Discovery and Development

4.2.3 Rising outsourcing of complex protein conjugation to CDMOs/CROs

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.2.4 Technology Advancements Such as Site-Specific Labeling and Others
- 4.2.5 Increasing Use of Fluorescence Based Techniques
- 4.2.6 Growing adoption of companion diagnostics and precision-medicine assays
- 4.3 Market Restraints
 - 4.3.1 Limitations Associated with Protein Labelling Assays and Methods
 - 4.3.2 Regulatory complexity around protein-radioisotope conjugate
 - 4.3.3 High capital cost of high-resolution mass-spectrometry work-flows
 - 4.3.4 Limited shelf-life and stability issues of many labelled reagents
- 4.4 Value / Supply-Chain Analysis
- 4.5 Regulatory and Technological Outlook
- 4.6 Porter's Five Forces Analysis
 - 4.6.1 Bargaining Power of Suppliers
 - 4.6.2 Bargaining Power of Buyers
 - 4.6.3 Threat of New Entrants
 - 4.6.4 Threat of Substitutes
 - 4.6.5 Intensity of Competitive Rivalry

5 Market Size and Growth Forecasts (Value-USD)

- 5.1 By Product
 - 5.1.1 Reagents and Kits
 - 5.1.2 Services
 - 5.1.3 Other Products (Spin columns, Resins, etc.)
- 5.2 By Application
 - 5.2.1 Immunological Techniques
 - 5.2.2 Cell-based Assays
 - 5.2.3 Fluorescence Microscopy
 - 5.2.4 Protein Microarrays
 - 5.2.5 Mass Spectrometry
- 5.3 By Labelling Method
 - 5.3.1 In-vitro Labelling
 - 5.3.2 In-vivo Labelling
- 5.4 By End User
 - 5.4.1 Pharmaceutical and Biotechnology Companies
 - 5.4.2 Contract Research and Manufacturing Organisations (CROs/CDMOs)
 - 5.4.3 Academic and Research Institutes
 - 5.4.4 Clinical Diagnostics Laboratories
- 5.5 By Geography
 - 5.5.1 North America
 - 5.5.1.1 United States
 - 5.5.1.2 Canada
 - 5.5.1.3 Mexico
 - 5.5.2 Europe
 - 5.5.2.1 Germany
 - 5.5.2.2 United Kingdom
 - 5.5.2.3 France
 - 5.5.2.4 Italy
 - 5.5.2.5 Spain

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.5.2.6 Rest of Europe

5.5.3 Asia-Pacific

5.5.3.1 China

5.5.3.2 Japan

5.5.3.3 India

5.5.3.4 South Korea

5.5.3.5 Australia

5.5.3.6 Rest of Asia-Pacific

5.5.4 Middle East and Africa

5.5.4.1 GCC

5.5.4.2 South Africa

5.5.4.3 Rest of Middle East and Africa

5.5.5 South America

5.5.5.1 Brazil

5.5.5.2 Argentina

5.5.5.3 Rest of South America

6 Competitive Landscape

6.1 Strategic Moves

6.2 Market Share Analysis

6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)

6.3.1 Thermo Fisher Scientific Inc.

6.3.2 Merck KGaA

6.3.3 Danaher Corp.

6.3.4 Revvity

6.3.5 F. Hoffmann-La Roche AG

6.3.6 Agilent Technologies Inc.

6.3.7 Bio-Rad Laboratories Inc.

6.3.8 KMD Bioscience Co., Ltd.

6.3.9 Promega Corporation

6.3.10 LI-COR Biotech, LLC

6.3.11 New England Biolabs Inc.

6.3.12 Takara Bio Inc.

6.3.13 Vector Laboratories Inc.

6.3.14 Jena Bioscience GmbH

6.3.15 Lumiprobe Corp.

6.3.16 Biotium Inc.

6.3.17 Abcam plc

6.3.18 Creative Diagnostics

6.3.19 Cyanagen Srl

6.3.20 Genscript

7 Market Opportunities and Future Outlook

7.1 White-Space and Unmet-Need Assessment

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Protein Labeling - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-06-01 | 105 pages | Mordor Intelligence

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2026-03-03
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com